Enterovirus 71 (EV71) is a causative agent of hand, foot and mouth disease (HFMD). EV71 causes fever, rash, diarrhoea and, in some cases, acute encephalopathy/encephalitis, which can be fatal. No specific treatment is currently available for EV71 infection. Here, we conducted a cDNA library screen and identified acid b-glucosidase 1 (GBA1; also known as bglucocerebrosidase) as an EV71 resistance factor. The anti-EV71 function of GBA1 was verified by gene transduction and knockdown experiments. Cerezyme, a molecular drug used to treat Gaucher's disease and having recombinant human GBA1 as the active ingredient, protected against EV71 infection. The anti-EV71 activity of GBA1 was bimodal: endogenous GBA1 restricted cell surface expression levels of scavenger receptor class B, member 2 (SCARB2), also known as lysosomal integral membrane protein 2 (LIMP-2), and exogenous recombinant GBA1 interfered with EV71 to interact with SCARB2 outside the cell. Thus, our findings suggest that GBA1 may represent a novel molecular target for the treatment of EV71 infection.
INTRODUCTION
Hand, foot and mouth disease (HFMD), a syndrome characterized by fever and maculopapular rashes on the hands, feet or lips, commonly affects infants and young children in summer [1] . The clinical course of HFMD is mostly mild and self-limiting, and members of the Enterovirus genus of the Picornavirus family, namely Coxsackievirus (CAV) A16 and enterovirus 71 (EV71) [2] , are the major aetiological agents of this disease. Some patients with EV71-induced HFMD, unlike those infected with CAV, develop severe complications, including acute flaccid paralysis, aseptic meningitis and brain stem encephalitis, which may lead to fatal outcomes [3] . No specific medications or vaccines are currently available to treat HFMD. HFMD outbreaks involving EV71 have occurred in several south-east Asian countries [4] [5] [6] [7] . Moreover, between 2008 and 2012, 2457 patients died from EV71 infection in China [8] .
Recent advancements have improved our understanding of EV71-host interactions at the molecular level. In 2009, researchers reported the discovery of two EV71 receptors, i.e. human scavenger receptor class B, member 2 (SCARB2), also known as lysosomal integral membrane protein 2 (LIMP-2) or CD36b like-2; and P-selectin glycoprotein ligand-1 (PSGL-1), also known as CD162 [9] [10] [11] . SCARB2 is expressed in most cell types, whereas PSGL-1 is limited to blood cells and endothelial cells, suggesting a distinct role for these two receptors in the pathogenesis of EV71 infection in vivo [12] . An important physiological function of SCARB2 is to transport acid b-glucosidase 1 (GBA1; also known as b-glucocerebrosidase), thereby supporting glycolipid metabolism [13] . GBA1 associates with SCARB2 soon after synthesis in the endoplasmic reticulum (ER). This molecular complex is trafficked through the Golgi to lysosomes. The acidic conditions in the lysosome trigger the dissociation of GBA1 from SCARB2. A mutation in SCARB2 was found to cause downregulation of GBA1 expression in epithelial cells [14] , suggesting that SCARB2 may function as a molecular chaperone of GBA1. Factors that enhance EV71 infection have also been reported, including annexin II and heparin sulfate [14, 15] . More recently, positive cellular regulators of EV71 replication have been characterized IP: 54.70.40.11
On: Thu, 27 Dec 2018 18:58:22 [8, 16, 17] . However, intrinsic negative regulators of EV71 replication have not been documented.
To identify cellular regulators of viral replication, it is informative to compare cell lines bearing a high susceptibility to viral infection with those showing poor susceptibility. In this study, we identified a cellular factor that limited EV71 replication using a cell line showing poor support for EV71 replication.
RESULTS

Genetic screen of EV71 resistance genes in U251MG cells
We assessed the susceptibility of various human cell lines to EV71 infection and found that the astrocytoma cell line U251MG poorly supported EV71 replication. In RD18S cells, a cell line highly permissive to EV71 infection that has been used in the isolation of EV71 from clinical specimens, the virus titre in the culture supernatant was 10 5 -10 6 tissue culture infectious dose 50 (TCID 50 ). In contrast, U251MG cells yielded an EV71 titre of 10 3 -10 4 TCID 50 . Thus, we hypothesized that there could be a cellular inhibitor of EV71 replication in U251MG cells. To identify this factor, we constructed a cDNA library generated from U251MG cells and transduced it into RD18S, U251MG and 293T cells using a retroviral vector. Cells were exposed to EV71 such that viral-infected cells were killed by the virus within a few days, releasing progeny viruses and accelerating the cytolysis of surrounding cells. At 2 weeks after viral exposure, two EV71-resistant cell clones were obtained from U251MG cells, whereas none were isolated from the other cell lines; the reason for this difference may be that the susceptibility to EV71 infection was low in U251MG cells compared with other cell lines (see Discussion).
Next, we examined whether two cell clones were indeed resistant to EV71. The cytopathic effect (CPE) of EV71 is induction of cell death. Thus, the cell survival rate reflecting the CPE of EV71 was measured by luminescence, which was related to the concentration of ATP in living cells. Two clones showed no detectable loss of cell viability when grown under conditions in which parental U251MG cells were killed by EV71 (Fig. 1a) . cDNA was analysed in the cell clones transduced with the retroviral vector, and reverse transcription PCR (RT-PCR) amplified~3 kbp bands in both clones that were slightly different in length (Fig. 1b) . Sequence analysis revealed that both amplicons spanned the full length of the GBA1 gene and contained differences in the lengths of the untranslated regions. Immunoblot analysis revealed that GBA1 expression was higher in U251MG cell clones isolated from the genetic screen than in the parental cells (Fig. 1c) . Similarly, the fluorescence signal intensity representing GBA1 expression was high in the two clones in an immunofluorescence assay (Fig. 1d) . GBA1 was distributed unevenly in the cytoplasm. Consistent with these findings, a biochemical assay revealed that the acid glucosidase activity in the cell lysate was significantly higher in these two clones than in the parental U251MG cells (Fig. 1e) , although this reflected not only GBA1 activity but also that of other acid b-glucosidases.
Three GBA subfamilies, i.e. GBA1, -2 and -3, hydrolyse glycosides. Mutations in the GBA1 gene result in Gaucher's disease, a lysosomal storage disorder, and are associated with Parkinson's disease in some individuals [18] [19] [20] . GBA3 has a molecular weight similar to that of GBA1 but has distinct intracellular distribution. Thus, we used GBA3 as a specificity control.
Verification of the anti-EV71 function of GBA1 To verify the above findings, U251MG cells were transfected with a GBA1 expression plasmid, and cell clones stably overexpressing GBA1 were isolated, as verified by immunoblotting (Figs 2a and S1 , available in the online Supplementary Material). The viral titres in the culture supernatants of two GBA1-overexpressing clones were in the order of 10 2.8 TCID 50 , which was lower than that in the control by 31.2-fold (10 4.1
-10
4.4 TCID 50 ; Fig. 2a ). Following EV71 exposure, the viability of the two clones overexpressing GBA1 was greater than that of the corresponding controls (Fig. 2a) .
Next, the biological effects of GBA1 were investigated using small interfering RNA (siRNA)-mediated knockdown of endogenous GBA1 in transient transfection assays in 293T cells. The level of endogenous GBA1 was affected more by transfection with siGBA1#2 than by transfection with siGBA1#1, as demonstrated by immunoblotting (Fig. 2b) . The viral titres in the culture supernatant of siGBA1# 2-transfected cells were increased by 3.4-fold (Fig. 2b) . EV71-induced death of 293T cells was augmented by the reduction of endogenous GBA1 (Fig. 2b) . These data suggested that the viral yield and cell survival rate were inversely correlated.
In transient transfection assays in 293T cells, ectopic expression of GBA1 rendered cells resistant to EV71-induced cell death in a concentration-dependent manner (Fig. 2c) . Such activity was not observed for GBA3 (Fig. 2d) . In transfected 293T cells, GBA1 was mainly distributed in the cytoplasm, consistent with our previous data ( Fig. 1d versus Fig. 2d ), although GBA1 also localized to the perinuclear SCARB2-enriched lysosomal compartment (Fig. 2d) . GBA1 exerted no observable anti-viral effects against other enterovirus species, including echovirus 6 and CAV B3 (Fig. 2e) . These data suggested that GBA1 was an intrinsic resistance factor against EV71. Inhibition of the enzyme activity of GBA1 by the GBA inhibitor conduritol B epoxide did not alter the susceptibility of cells to EV71 infection (data not shown), suggesting that the physical presence of GBA1 protein, not its enzyme activity, was critical for its anti-EV71 function.
Analysis of the anti-EV71 mechanism of GBA1
The anti-EV71 function of GBA1 was examined based on the ability of GBA1 to bind to SCARB2, an EV71 receptor [13] . We investigated cell surface levels of SCARB2 in U251MG clones that expressed high levels of GBA1. Flow cytometric analyses revealed that the two representative clones that highly expressed GBA1 had lower levels of cell surface SCARB2 than their corresponding control (Figs 3 and S1), suggesting that the cell surface levels of SCARB2 were reduced by GBA1 expression. Given the transporter activity of SCARB2 [13, 14] , it seems likely that GBA1 overexpression may increase SCARB2 trafficking through the ER-Golgilysosome pathway, resulting in a reduction in SCARB2 targeting to the cell surface.
Anti-EV71 effects following treatment of cells with recombinant GBA1
Next, we investigated whether exogenous GBA1 also functioned as an inhibitor of EV71 infection. To this end, we utilized Cerezyme, an approved medicine for the treatment of Gaucher's disease, containing a purified recombinant human GBA1 protein [21] . Cells were infected with EV71 in the presence of Cerezyme and we assessed the virus cytolytic effect. Using this protocol, the cells were continuously exposed to Cerezyme until they were harvested for the cell viability assay. Cerezyme protected U251MG cells from EV71-induced death in a concentration-dependent manner at concentrations of 10-100 µg ml À1 (Fig. 4a ). Similar observations were made in RD18S cells (Fig. 4b) . We also examined the effects of Cerezyme on eight field isolates of EV71 that originated from patients with HFMD or herpangina. Treatment with Cerezyme at 100 µg ml À1 protected cells from the cytolytic activity of all EV71 strains tested, with efficiencies of 21.2-99.7 % (Fig. 4c ). On: Thu, 27 Dec 2018 18:58:22
anti-GBA1 Analysis of the anti-EV71 mechanism of recombinant GBA1 Flow cytometric analysis was conducted to investigate the anti-EV71 mechanism of recombinant GBA1 treatment by detecting the cell surface levels of SCARB2 after GBA1 treatment. If the anti-EV71 mechanism of exogenous GBA1 was identical to that of endogenous GBA1, the cell surface level of SCARB2 should be decreased. Surprisingly, however, exposing cells to purified recombinant GBA1 for 30 min (not Cerezyme) resulted in a modest increase in cell surface SCARB2 expression (Fig. 4d , blue versus green). In this experimental setting, the addition of recombinant GBA1 did not interfere with the efficiency of SCARB2 detection by antibodies (Fig. 4d, red) . These data suggested that the anti-EV71 mechanism of exogenous GBA1 was distinct from that of endogenous GBA1. It is possible, however, that this upregulation is transient and the cell surface SCARB2 expression may be downregulated after a longer incubation. In that case, the anti-EV71 mechanism of exogenous GBA1 is similar to that of endogenous GBA1.
Anti-EV71 effects of Cerezyme on human lymphoid cell lines Cells of lymphoid origin express SCARB2 and PSGL-2 as EV71 receptors [9] . However, the relative contribution of these two receptors has not been fully defined. To address this, we examined the effects of Cerezyme on EV71 infection in B and T cells. Generally, lymphoid cell lines poorly support EV71 infection. However, the human B-cell line NAMALWA and the T-cell line ED were highly susceptible to EV71 infection. Flow cytometric analysis showed that both cell lines were positive for SCARB2 and PSGL-2 (data not shown). Treatment with Cerezyme at 100 µg ml À1 inhibited EV71-induced cytolysis in NAMALWA cells, but these effects were not as robust as those observed in epithelial cells (Fig. 4e, left panel) . Treatment with Cerezyme at 0.1-100 µg ml À1 did not inhibit EV71 infection in ED cells (Fig. 4e, right panel) . These data suggested that Cerezyme protected lymphoid cells from EV71 . Protection of the cells from virus-induced cytolysis was assessed at 4 days post-infection by measuring cell viability in the presence of Cerezyme (black bars) relative to that of the uninfected control (white bar). Cell viability in the absence of Cerezyme is shown in grey. RLU, relative light units. (d) Effects of GBA1 treatment on cell surface levels of SCARB2. RD18S cells were treated with purified human GBA1 at a concentration of 1.2 µg ml À1 for 30 min at 37 C. Cell surface levels of SCARB2 were analysed by flow cytometry using anti-SCARB2 antibodies from R&D Systems (shown in blue). SCARB2 levels without GBA1 treatment are shown in green. Reactivity of anti-SCARB2 antibodies was not affected by GBA1 because co-treatment of fixed RD18S cells with two probes resulted in a profile similar to that observed with antibodies only (red versus green). RFU, relative fluorescence units. Representative data from two independent experiments are shown. (e) Cells of B and T lymphoid origins, respectively, were exposed to EV71 at an m.o.i. of 1 in the presence of the indicated concentrations of Cerezyme. NAMALWA and ED cells are human B-and T-cell lines, respectively. Cell viability was measured at 5 days post-infection. Means and standard deviations of triplicate wells are shown. Asterisks indicate statistically significant differences compared with the uninfected control (P<0.001, Student's two-sided t-test). RLU, relative light units.
infection; however, its effects were weak, presumably because of the presence of EV71 receptors other than SCARB2.
DISCUSSION
SCARB2 serves as a transporter of GBA1 from the ER to lysosomes [13] . The SCARB2 binding site for GBA1 partly overlaps with that of EV71 [22] [23] [24] . It is likely that exogenous GBA1 physically competes with EV71 to bind to SCARB2, leading to the inhibition of EV71 infection. However, endogenous GBA1 is also thought to allow SCARB2 to traffic via the ER-Golgi-lysosomal route, thereby reducing the amount of SCARB2 recruited to the cell surface. In this way, endogenous GBA1 limits EV71 infection. It is possible, however, that endogenous GBA1 exerts its anti-EV71 effects through other mechanisms for a slight downregulation of cell surface SCARB2 expression. Few intrinsic negative regulators of viral infection have been reported to act through the attenuation of receptor trafficking [25] . To the best of our knowledge, our finding is unique in this regard. SCARB2 supports the entry of other HFMD-causing enteroviruses [26] . The anti-viral potential of recombinant GBA1 may be applicable to other enterovirus infections.
Unlike its function as a transporter of GBA1 inside cells, where the majority of SCARB2 is localized, the physiological function of cell surface-localized SCARB2 is poorly understood. Two pathophysiological functions of cell surfacelocalized SCARB2 are proposed here. First, GBA1-unbound SCARB2 localizes to the cell surface, where SCARB2 traps extracellular GBA1 and transports it to the lysosome. This mechanism could explain the therapeutic effects of Cerezyme in Gaucher's disease [21] . Our findings indicated that once this pathway was activated, cell surface recruitment of SCARB2 was accelerated (Fig. 4d) , suggesting that this function was a safeguard for glycolipid metabolism. Second, SCARB2 serves as a receptor for EV71. Although it increases the cell surface levels of SCARB2, exogenous GBA1 limits EV71 infection by competitively binding to SCARB2.
Our genetic screen failed to isolate EV71-resistant cell clones from RD18S and 293T cells; however, multiple clones were isolated from U251MG cells. This result may be explained by the observation that U251MG cells are poorly susceptible to EV71 infection owing to their low surface levels of SCARB2; thus, ectopic GBA1 can sufficiently downregulate SCARB-2 expression such that U251MG cells can survive the screen. In addition, SCARB2 may be the only receptor available to EV71 in U251MG cells [23] .
In this study, we demonstrated the protective effects of recombinant GBA1 against EV71 infection in a tissue culture model. No molecular therapy against EV71 infection has been established. Thus, our findings may provide insights into not only the molecular interactions between the host and virus but also the therapeutic approach for EV71 infection. However, the relative role of PSGL-2 in the pathogenesis of EV71 infection should be also clarified. In addition, it will be necessary to establish a scientific basis for this potential therapeutic role of GBA1 by conducting experiments in mouse models, e.g. assessing the ability of Cerezyme to control EV71 infection in vivo, although the relevance of small animal models to the pathology of EV71 in humans is still controversial [11, 15] .
METHODS
Cells and transfection
Cells were maintained in RPMI 1640 (Wako) supplemented with 10 % FBS (Japan Bioserum), penicillin and streptomycin (Wako). Details for U251MG, 293T, ED and Namalwa cell culture were described previously [27] [28] [29] [30] [31] . RD18S cells were a generous gift from Kyoko Akiyoshi at the Kobe Institute of Health, Japan. 293A cells were purchased from Thermo Fisher Scientific. Cells were cultured at 37 C in a humidified atmosphere of 5 % CO 2 in air. Cells were transfected with plasmids or siRNA using Lipofectamine 2000 (Invitrogen).
Recombinant purified GBA1
Recombinant human GBA1 was purchased from Abnova. Cerezyme was purchased from Genzyme.
Plasmids, siRNA and virus vector
The mammalian expression vectors pME GBA1 and GBA3 were purchased from the National Institute of Technology and Evaluation Biological Resource Center, Japan. A plasmid vector containing SCARB2-GFP was a kind gift from Dr Jovic at the National Institutes of Health, USA [32] . The siRNA AccuTarget was purchased from Bioneer. The cDNA library generated from U251MG cells was cloned into the pMX retroviral vector [33] . The murine leukaemia virus (MLV) vector pseudotyped with vesicular stomatitis virus G protein (VSV-G) was produced as described previously [27] .
Isolation of EV71-resistant cell clones
Target cells grown in T25 flasks (Iwaki) were exposed to the MLV vector and fed into T50 flasks (Iwaki) 4 h after exposure. Cells were selected in tissue culture medium containing 1 µg puromycin ml À1 (Sigma) for 1 week. Thereafter, EV71 was inoculated into a tissue culture flask. Cell colonies that emerged 2-3 weeks after selection were picked and propagated in multi-well plates. U251MG cell clones constitutively expressing GBA1 were isolated by co-transfecting cells with pME GBA1 along with pPUR (Clontech) and selected with puromycin as described above. Control cell clones were isolated by transfecting pPUR alone.
RT-PCR
Total RNA was isolated using a GC series Magtration-MagaZorb RNA Common N Kit (Precision System Science). cDNA transduced by the retroviral vector was amplified by RT-PCR using the following primers: 1 st F 5¢-GGACCA TCCTCTAGACTGCCGG-3¢ and 1 st R 5¢-ATACTTC TGCCTGCTGGGGACC-3¢ (initial PCR); 2nd F 5¢-GAC TGCCGGATCCCAGTGTG-3¢ and 2nd R 5¢-CTGC TGGGGAGCCTGGGGAC-3¢ (nested PCR). Viruses EV71, echovirus and CAV strains were isolated on RD18S cells at the Osaka Prefectural Institute of Public Health, Japan, in a pathogen surveillance of HFMD and herpangina. The ME40 and ME42 strains were used for most studies and were propagated in RD18S or 293T cells. ME71 and ME72 were isolated from patients with herpangina. Viral titration was performed using RD18S cells or 293A cells. Specimens were serially diluted in a 10-fold series from 1 : 10 to 1 : 10 7 . A flat-bottomed 96-well tissue culture plate was fed with 2Â10 3 cells per well in a volume of 100 µl. At 1 day after plating, cells were exposed to the specimen for 30 min and maintained in the same volume in RPMI 1640 supplemented with 2 % FBS after washing. Each dilution point was examined in eight replicates. CPE was examined under microscopy at 3-4 days post-infection. TCID 50 was calculated using the Reed-Muench method.
Cell viability assay A CellTiter-Glo Luminescent Cell Viability Assay kit (Promega) was used to measure cell viability. Luminescence was measured using a Varioskan reader (Thermo Fisher Scientific).
Western blotting
Western blotting was performed according to standard techniques. The following reagents were used to detect the signal: rabbit anti-GBA1 polyclonal antibodies (Sigma), anti-GBA1 monoclonal antibodies (Abnova), rabbit antiactin polyclonal antibodies (BioVision), anti-HSP90 monoclonal antibodies (BD Transduction Laboratories), a ChemMate Envision kit utilizing HRP (Dako) and a TMB SUBSTE Kit (Vector Laboratories).
Immunofluorescence assay
Immunofluorescence assays were performed as described previously [34] , and samples were imaged using a confocal laser-scanning microscope (TCS SPE; Leica). For staining, anti-GBA1 monoclonal antibodies (Abnova) and Alexa 555-conjugated goat anti-mouse antibodies (Invitrogen) were used.
Flow cytometry
The cell surface levels of SCARB2 were analysed by flow cytometry (FACS Calibur; BD Biosciences) using the following reagents: biotinylated goat anti-SCARB2 polyclonal antibodies (R&D Systems), phycoerythrin-conjugated streptavidin (R&D Systems), rabbit anti-SCARB2 polyclonal antibodies (Atlas), Alexa 488-conjugated anti-rabbit IgG (Invitrogen), rabbit anti-SCARB2 monoclonal antibody (EPR12080; Abcam), rabbit IgG isotype control (Abcam), Alexa Fluor 647-conjugated goat anti-rabbit antibody (Abcam), FITC-conjugated anti-CD162 mouse monoclonal antibody (TC2; Abcam) and mouse monoclonal antibody as an isotype control (Abcam).
b-Glucosidase activity assay Cells were lysed in 0.2 % NP-40 prepared in PBS. Lysates of 2Â10 5 cells were incubated at 37 C for 1 h in 110 µl reaction buffer containing 200 M 4-methylumbelliferyl b-D-glucopyranoside and 30 mM sodium acetate. The reaction was stopped by the addition of 10 µl NaOH (1 M). Fluorescence was measured using a Varioskan reader with excitation at 360 nm and emission at 449 nm.
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